http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004097429-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2eef6055fd22683d10d1bcbf8e649c12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_798752a67e5eff9dce01bfda2a75346d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
| filingDate | 2004-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f65fec67f12851ec49ee871d6c257977 |
| publicationDate | 2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2004097429-A3 |
| titleOfInvention | Apociii and the treatmentand diagnosis of diabetes |
| abstract | The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes by identifying those test compounds that inhibit an apoCIII- induced increase in intracellular calcium concentration in pancreatic β cells. The present invention further provides methods for treating patients with type I diabetes by administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells. The present invention provides methods for diagnosing Type I diabetes or a propensity to develop type I diabetes by comparing an amount of sialylated apoCIII in a blood serum sample from a subject with an amount of sialylated apoCIII in a control blood serum sample and diagnosing those subjects with an elevated amount of sialylated apoCIII in the blood serum sample relative to the control as having type I diabetes, or having a propensity to develop type I diabetes. The present invention provides methods for identifying diabetic patients to be treated with anti-apoCIII therapy, by determining an amount of apoCIII in a blood serum sample from a diabetic subject and comparing it to a control blood serum sample; and identifying those subjects with an elevated amount of apoCIII in the blood serum sample relative to the control blood serum sample as being subjects to be treated with anti-apoCIII therapy. |
| priorityDate | 2003-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559505 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460341 |
Total number of triples: 31.